Filing Details

Accession Number:
0001214659-20-009726
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-18 16:36:12
Reporting Period:
2020-11-16
Accepted Time:
2020-11-18 16:36:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737287 Allogene Therapeutics Inc. ALLO Biological Products, (No Disgnostic Substances) (2836) 823562771
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754403 Thomas Eric Schmidt 210 East Grand Avenue
South San Francisco CA 94080
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-11-16 4,634 $32.60 1,192,961 No 4 S Indirect See footnote
Common Stock Disposition 2020-11-16 10,366 $33.00 1,182,595 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 78,916 Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.93 to $32.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.93 to $33.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.